However, mutation of TP53 and the resultant inactivation of p53 allow evasion of tumour cell death and rapid tumour progression. The high frequency of TP53 mutation in tumours has prompted efforts to restore normal function of mutant p53 and thereby trigger tumour cell death and tumour elimination...
In this study, more than three hundred colorectal cancer patients' samples were firstly analyzed, and the results showed that patients with mutant p53 had higher levels of AKT phosphorylation and PD-L1 expression, which were next verified both in cell lines in vitro and patients' samples in ...
Feng Z. Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol. 2020 ...
为庆祝这一事件,2024年5月9日,美国哥伦比亚大学欧文医学中心顾伟教授课题组(刘彦卿博士为第一作者)应邀在Cancer Cell杂志撰写了题为:Understanding the complexity of p53 in a new era of tumor suppression的长文综述。 该综述全方位地总结了p53的...
peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines...
However, in cells that express very low levels of TAp63, the ability of mutant p53 to promote MET-dependent cell scattering was independent of TAp63. Taken together, our data show that mutant p53 can enhance MET signalling to promote cell scattering and invasion through both TAp63-dependent ...
PDGFRb Mediates Mutant p53 Action in Human Cancer Cells To determine if the mutant p53-PDGFRb signaling axis acts in human cancer cells, we analyzed PDGFRb expression levels in a panel of human pancreatic cancer cell lines. As in our model, PDGFRb mRNA levels were significantly higher in cells...
(D and E) Cell viability assay for the indicated cell lines upon ATO treatment for 72 h. On the right side of (D), the dots represent the calculated IC50. In (E), mutant p53 in the indicated three cell lines was knocked down by siRNA, followed by cell viability assay. (F–H) Res...
6c). Similar results were also observed beyond CRC cell lines, PARP1 was activated by SC66 treatment in HepG2 cells with wild type p53, but not in DU145 cells, with mutant p53 (Fig. 6d). Next, in order to investigate whether p53 binds to PARP1 directly, co-immunoprecipitation assay ...
5.https://www.nurixtx.com/pipeline/ 6.First Disclosure of NX-5948, an Oral Targeted Degrader of Bruton's Tyrosine Kinase (BTK) for the Treatment of B-cell Malignancies 7.First Disclosure of NX-2127, an oral targeted degrader of Bruton’s tyrosine kinase (BTK) with concurrent ...